Compassionate Use of Pozelimab
Sponsor
Regeneron Pharmaceuticals (Industry)
Overall Status
Available
CT.gov ID
NCT05232110
Collaborator
(none)
Study Details
Study Description
Brief Summary
Provide compassionate use of pozelimab
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Study Design
Study Type:
Expanded Access
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Regeneron Pharmaceuticals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT05232110
Other Study ID Numbers:
- R3918-Pozelimab
First Posted:
Feb 9, 2022
Last Update Posted:
Feb 9, 2022
Last Verified:
Jan 1, 2022
Additional relevant MeSH terms: